Study guide
7.3 HLA, Platelet-Specific & Granulocyte Antigens
Specialist in Blood Banking, SBB ASCP
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current Exam Facts 1.2 Eligibility Routes & Credential Maintenance 1.3 Study Strategy for SBB
2 Donors & Collection
2.1 Donor Qualification 2.2 Collection Methods & Adverse Reactions 2.3 Special Donations
3 Processing, Storage & Component QC
3.1 Processing, Testing & Labeling 3.2 Storage, Transport & Expiration 3.3 Blood Component Quality Control
4 Red Cell & Modified Components
4.1 Whole Blood & Red Blood Cells 4.2 Leukocyte-Reduced, Washed, Frozen & Rejuvenated RBCs 4.3 Irradiated Components 4.4 Granulocytes
5 Platelets, Plasma & Cellular Products
5.1 Platelets 5.2 Plasma & Cryoprecipitated AHF 5.3 Apheresis Products & Fractionation Products 5.4 Hematopoietic Progenitors
6 Genetics, ABO & Rh
6.1 Blood Group Genetics & Molecular Inheritance 6.2 ABO & Lewis Systems 6.3 Rh System 6.4 MNS, P1PK/Globoside & Ii
7 Other Blood Groups & Role in Transfusion
7.1 Kell, Kidd, Duffy & Lutheran 7.2 Other Systems & High/Low-Prevalence Antigens 7.3 HLA, Platelet-Specific & Granulocyte Antigens 7.4 Immunogenicity & Antigen Prevalence
8 Immunology Foundations
8.1 Immune Response 8.2 Immunoglobulins 8.3 Antigen-Antibody Interactions 8.4 Complement
9 Physiology, Hemostasis & HDFN
9.1 Physiology of Blood 9.2 Hemostasis and Coagulation 9.3 HDFN Pathophysiology & Detection 9.4 HDFN Treatment & Prevention
10 Cytopenias & Transplantation
10.1 Immune & Nonimmune Anemia 10.2 Thrombocytopenia & Neutropenia 10.3 Solid Organ Transplantation Support 10.4 Hematopoietic Progenitor Cell Transplantation
11 Routine Serologic Testing
11.1 Blood Grouping Tests 11.2 Antibody Detection & Crossmatch 11.3 Antibody Identification & Clinical Significance 11.4 Direct Antiglobulin Testing & Reagents
12 Special Serologic Methods
12.1 Enzymes, Enhancement Media & Lectins 12.2 Adsorptions, Elutions & Titrations 12.3 Cell Separations, Neutralization & Thiol Reagents 12.4 Chloroquine Diphosphate & EDTA-Glycine Acid
13 Molecular Platforms & Serologic QA
13.1 Molecular Blood Group Techniques 13.2 ELISA, Immunofluorescence, Solid Phase & Column Agglutination 13.3 Serologic Quality Assurance
14 Indications, Component Therapy & PBM
14.1 Indications for Transfusion 14.2 Component Therapy 14.3 Blood Administration & Patient Blood Management
15 Adverse Effects of Transfusion
15.1 Immunologic Transfusion Reactions 15.2 Nonimmunologic Reactions 15.3 Transfusion-Transmitted Diseases
16 Apheresis & Extracorporeal Circulation
16.1 Therapeutic Apheresis 16.2 Extracorporeal Circulation
17 Quality, Safety, Math & Instrumentation
17.1 Quality Assessment & Troubleshooting 17.2 Laboratory Safety 17.3 Laboratory Mathematics 17.4 Instrumentation
18 Laboratory Administration (SBB Only)
18.1 Financial Management 18.2 Operations & Information Technology 18.3 Personnel, Education & Training 18.4 Quality Management, Risk & Tissue Management
7.3 HLA, Platelet-Specific & Granulocyte Antigens
Key Takeaways Explain This Topic AI
HLA Class I antigens on platelets drive alloimmunization from pregnancy or prior transfusion, leading to platelet refractoriness measured by a persistently low corrected count increment
Universal leukoreduction of cellular blood components reduces the rate of primary HLA alloimmunization
Donor anti-HLA or anti-HNA antibodies, often from multiparous female donors, activate primed recipient neutrophils in the two-hit model of TRALI
Anti-HPA-1a is the most common cause of fetal/neonatal alloimmune thrombocytopenia and of post-transfusion purpura in HPA-1a-negative individuals
Post-transfusion purpura destroys both transfused and autologous platelets five to ten days after transfusion and is treated with IVIG rather than further platelet transfusion
Last updated: July 2026
HLA, Platelet-Specific & Granulocyte Antigens
Quick Answer: Beyond red cell antigens, the human leukocyte antigen (HLA) system, platelet-specific human platelet antigens (HPA), and human neutrophil antigens (HNA) drive a distinct set of transfusion complications: HLA alloimmunization causes platelet refractoriness and is a leading trigger of transfusion-related acute lung injury (TRALI); HPA antibodies (most often anti-HPA-1a) cause fetal/neonatal alloimmune thrombocytopenia and post-transfusion purpura; and HNA antibodies contribute to TRALI, febrile reactions, and neonatal alloimmune neutropenia. Leukoreduction of cellular blood products is the primary strategy for reducing new HLA alloimmunization, while donor-screening policies target implicated antibodies rather than antigens.
The HLA System in Transfusion Medicine
HLA Class I molecules (HLA-A, -B, -C) are expressed on essentially all nucleated cells and, importantly for transfusion, on platelets, while HLA Class II molecules (HLA-DR, -DQ, -DP) are restricted to antigen-presenting cells such as B lymphocytes, monocytes, dendritic cells, and activated T cells. Repeated exposure to allogeneic leukocytes — through pregnancy or prior transfusion of cellular blood products — can immunize a recipient against HLA Class I antigens. Once alloimmunized, a patient may develop platelet refractoriness: platelet transfusions fail to produce the expected rise in platelet count despite ABO-compatible, adequately dosed, fresh product. Refractoriness is quantified with the corrected count increment (CCI), which adjusts the post-transfusion platelet rise for the patient's body surface area and the number of platelets transfused; a persistently low CCI on two or more sequential transfusions, in the absence of a nonimmune cause such as sepsis, DIC, or splenomegaly, points toward HLA (or, less often, HPA) alloimmunization. Management options include HLA-matched apheresis platelets from a matched unrelated donor registry or platelet crossmatching to identify compatible units. Universal leukoreduction of red cell and platelet components substantially lowers the rate of primary HLA alloimmunization by removing the white cells that present HLA antigens, a strategy validated in large trials of leukoreduced versus non-leukoreduced components.
HLA Class I (and, less commonly, HNA) antibodies present in donor plasma are also central to the pathophysiology of TRALI. In the accepted two-hit model, a recipient's neutrophils become primed and sequestered in the pulmonary microvasculature by an underlying clinical condition (the first hit); when a plasma-containing component from a donor carrying anti-HLA or anti-HNA antibodies is transfused, those antibodies bind and fully activate the sequestered neutrophils (the second hit), triggering release of proteases and reactive oxygen species that damage the capillary endothelium and produce acute, noncardiogenic pulmonary edema, typically within six hours of transfusion. Donor antibodies of this kind are disproportionately found in multiparous female donors, who may have been alloimmunized by fetal antigens during pregnancy. Blood centers mitigate this risk by preferentially collecting plasma and whole-blood-derived platelets from male donors or from female donors without a pregnancy history, and by testing implicated donors for HLA/HNA antibodies once a TRALI case is reported.
Platelet-Specific (HPA) Antigens
Human platelet antigens are polymorphisms on platelet membrane glycoproteins, most importantly the fibrinogen receptor GPIIb/IIIa, which carries the HPA-1a/HPA-1b polymorphism (formerly named PlA1/PlA2). HPA-1a is the most clinically important platelet-specific antigen because it is highly immunogenic and present in roughly 98% of the population, leaving a small HPA-1a-negative minority at risk of alloimmunization. Other systems include HPA-2 (on GPIbα), HPA-3 (on GPIIb), HPA-4 (on GPIIIa), and HPA-5 (on GPIa). Two clinical syndromes dominate the SBB-relevant discussion of HPA antibodies. Fetal and neonatal alloimmune thrombocytopenia (FNAIT) occurs when an HPA-1a-negative mother is sensitized against paternally inherited HPA-1a on fetal platelets; maternal IgG anti-HPA-1a crosses the placenta and destroys fetal platelets, and the most severe cases can present with fetal or neonatal intracranial hemorrhage, sometimes in a first pregnancy since sensitization can occur early in gestation. Post-transfusion purpura (PTP) occurs in an HPA-1a-negative patient previously sensitized by pregnancy or transfusion; five to ten days after a subsequent transfusion of any HPA-1a-positive cellular product, a brisk secondary antibody response destroys both the transfused platelets and the patient's own HPA-1a-negative platelets, through immune-complex or bystander mechanisms, producing severe, potentially life-threatening thrombocytopenia. PTP is treated with intravenous immunoglobulin (IVIG) and, in urgent bleeding, HPA-1a-negative platelets or plasma exchange; platelet transfusion of antigen-positive units generally does not help and can worsen the reaction.
Granulocyte (HNA) Antigens
Human neutrophil antigens reside on neutrophil membrane glycoproteins, including HNA-1 on the Fc receptor FcγRIIIb (CD16b) and HNA-2 on CD177. Antibodies against HNA antigens, like anti-HLA antibodies, are implicated in TRALI when present in donor plasma, and they can also cause febrile nonhemolytic transfusion reactions and, in the neonatal setting, neonatal alloimmune neutropenia when maternal anti-HNA crosses the placenta and destroys fetal neutrophils, leaving the newborn susceptible to infection until the antibody clears. Because HNA and HLA antibody testing require specialized reference-laboratory assays rather than routine blood bank methods, most facilities send suspected TRALI or neonatal alloimmune neutropenia cases out for confirmatory antibody identification while managing the acute presentation supportively.
Putting It Together: CCI and Antibody Workups
The corrected count increment ties several of these concepts together and is worth committing to memory: CCI = (post-transfusion platelet count minus pre-transfusion platelet count, in platelets per microliter) multiplied by body surface area in square meters, divided by the number of platelets transfused (×10¹¹). A one-hour CCI below roughly 7,500–10,000 on repeated occasions, without a nonimmune explanation, is the threshold most laboratories use to trigger an HLA antibody screen and consideration of HLA-selected or crossmatch-compatible platelets. The same logic of testing for an antibody once expected outcomes fail applies across this chapter: a fetus with unexplained anemia despite reassuring bilirubin trends prompts a Kell antibody workup, a newborn with unexplained thrombocytopenia and a sensitized mother prompts an HPA-1a workup, and a recipient with acute respiratory distress shortly after transfusion prompts a donor HLA/HNA antibody investigation.
Quick Reference
- Antigen System Location Key Complication
- HLA Class I All nucleated cells, platelets Platelet refractoriness, TRALI
- HLA Class II Antigen-presenting cells Alloimmunization risk
- HPA (e.g., HPA-1a on GPIIb/IIIa) Platelet glycoproteins FNAIT, post-transfusion purpura
- HNA (e.g., HNA-1 on FcγRIIIb) Neutrophil glycoproteins TRALI, neonatal alloimmune neutropenia